

## **Résumé**

**Marc Lapointe, B.S., Pharm.D., BCPS, BCNSP**

### **Business Address**

Medical University of South Carolina  
Department of Pharmacy and Clinical Services  
43 Sabin Street, Room QE-213  
P.O. Box 250132  
Charleston, SC 29425  
Tel.: (843) 792-8443  
Fax.: (843) 792-3759  
Pager: (843) 792-0950, #11963  
E-mail: lapointe@musc.edu

### **Education**

2005- Board Certification – Nutrition support (BCNSP)  
1997- Board Certification – Pharmacotherapy (BCPS)  
1995-1996 Specialty Practice Residency in Critical Care  
Medical University of South Carolina, Charleston.  
1993-1995 Doctor of Pharmacy  
Medical University of South Carolina, Charleston.  
1989-1993 Bachelor of Science in Pharmacy  
Université Laval, Québec, Canada  
1991 International Program  
University of New-Brunswick, Fredericton, Canada  
1990 Foreign Language Program  
University of Regina, Saskatchewan, Canada  
1987-1989 Diploma in Science Studies  
College of Chicoutimi, Québec, Canada

### **Professional Practice Experience**

#### **Medical University of South Carolina, Charleston**

1998- Clinical Specialist in Critical Care  
Department of Pharmacy and Clinical Services  
Department of Neurological Sciences  
1996- Clinical Coordinator (Drug delivery systems)  
Neurosurgery Spasticity Clinic  
1996-1998 Clinical Specialist in Critical Care  
Neurosurgery, surgery, trauma and burn intensive care units  
1995-1996 Critical Care Resident and Decentralized Pharmacist  
Surgical intensive care units

**Academic Appointments**Medical University of South Carolina, Charleston, SC

2004-	Associate Professor College of Medicine, Department of Neurological Surgery
2002-	Associate Professor College of Pharmacy, Department of Pharmacy Practice
1998-	Assistant Professor College of Medicine, Department of Neurological Surgery
1998-2002	Assistant Professor College of Pharmacy, Department of Pharmacy Practice
1997-	Residency Program Director (Critical Care) College of Pharmacy, Department of Pharmacy Practice
1996-1998	Clinical Instructor College of Pharmacy, Department of Pharmacy Practice

**Committee Appointments**Medical University of South Carolina, Charleston, SCHospital

2005-	Parenteral Nutrition Task Force
2004-	ICU Quality Improvement
2004-	Sedation Task Force
2001-	Stroke Task Force
2001-2003	Sepsis task force
1999-2004	Moderate sedation
1996-1998	Conscious sedation ( <i>Chair</i> )
1997-1998	Critical care & Nutrition

Department of Pharmacy and Clinical Services

2004-	Peer evaluation of teaching ( <i>Chair</i> )
2001-2002	Evaluation of teacher and practitioner models
1998-1999	Policy and Procedure - Pharmacists administering medications
1997-1998	Drug cart standardization
1996-1997	Formulary review

College of Pharmacy

2004-	Class advisor (class of 2008)
2004-	Appointment, Promotion and Tenure
2002-	Faculty affairs
2001-	International Affairs
2000-	Student advisor
1999-	Admission committee
1997-	Residency Programs
2002-2004	Faculty Senate
1999-2001	SNAPhA - advisor
1997-1999	Educational technology
1997-1999	Organization and administration self-study & Clinical therapeutics

**Professional Organizations**

2005-	Rho Chi
2005-	Kappa Psi
2003-	Journal of Clinical Therapeutics ( <i>Editorial consultant</i> )
2003-	American Association of Colleges of Pharmacy
2001-	Society of Critical Care Medicine, Carolina/Virginia Chapter ( <i>Board member</i> )
2001-	American Pharmaceutical Association ( <i>Abstracts reviewer</i> )
1999-	South Carolina Society of Hospital Pharmacists
1998-	South Carolina Pharmacy Association, License # 009739
1997-	American Society of Health-System Pharmacists
1997-	American College of Clinical Pharmacists
1995-	South Carolina Board of Pharmacy
1995-	Society of Critical Care Medicine
1995-	American Heart Association - Basic/Advanced Cardiac Life Support
1993-95	Québec Pharmacy Association
1991-93	Canadian Pharmaceutical Association
1992-93	Canadian Association of Pharmacy Students and Interns ( <i>President</i> )
1991-92	Canadian Journal of Pharmacy Students and Interns ( <i>Editor</i> )

**Publications**

- Goodin S, Lapointe M, Morreale AP. The evolution of erythropoietic therapy - Past, present, and future. *Pharm Pract News* 2005;April:45-51.
- Lewin J, Lapointe M. Therapeutic management of CNS infections. *J Pharm Prac* 2005;18:25-41.
- Lapointe M. Iron supplementation in the ICU: When, how much, what route? *Critical Care* 2004, 8(Suppl 2):S37-S41
- Givens M, Lapointe M. Is there a place for recombinant human erythropoietin alfa in managing anemia in the ICU? *Clin Ther* 2004;26:819-29.
- Williamson D, Lapointe M. Low-dose corticosteroids in septic shock. *Pharmacotherapy* 2003;23:514-25.
- Lapointe M, Haines SJ. Fibrinolytic therapy for intraventricular hemorrhage in adults. *International Cochrane Database*, 2002.
- Page RL, Ruscin JM, Fish D, Lapointe M. Possible interaction between intravenous azithromycin and oral cyclosporine. *Pharmacotherapy* 2001;21:1436-43.
- Hemstreet B, Lapointe M. Evidence for the use of gabapentin in the treatment of diabetic peripheral neuropathy. *Clin Ther* 2001;23:520-31.
- Haase KK, Lapointe M, Haines SJ. Aseptic meningitis after intraventricular administration of gentamicin. *Pharmacotherapy* 2001;21:103-7.
- Lapointe M, Baillie M, et al. Cyclosporin-induced hemolytic uremic syndrome and hemorrhagic colitis following renal transplantation. *Clin Transplant* 1999;13:526-30.
- Haines SJ, Lapointe M. Fibrinolytic agents in the management of posthemorrhagic hydrocephalus in preterm infants: The evidence. *Child's Nervous System* 1999;15:226-34.
- Lapointe M. Current trend in surgical prophylaxis. *J Infect Dis Pharmacother* 1998;3:17-39.
- Haines SJ, Lapointe M. Fibrinolytic agents in the treatment of intraventricular hemorrhage in adults. *Crit Rev Neurosurg* 1998;9:169-175.
- O'Neil MG, Lapointe M. Administration of amphotericin B in lipid emulsion. *Crit Care Med* 1997;25:892-3.

**Book Chapters**

- McCutcheon T, *Lapointe M*, Osenbach RK, Haines SJ. Choice of antibiotics in the prophylaxis and treatment of common neurosurgical problems. In: Batjer H, Loftus C. Textbook of Neurological Surgery. Lippincott-Raven, Philadelphia, 2002, Vol 4, pages 3098-3107.
- *Lapointe M*, Haines SJ, Landesman S. Basic principles of antimicrobial therapy of CNS infections. In: Cooper PR, Golfinos JG. Head Injury, Fourth Edition, McGraw-Hill:NY, 2000; pages 483-498.
- Le groupe des 11. Communiquer: la réponse dans votre sarrau. Book Sponsored by Whitehall Robins Canada Inc. regarding communication and patient counseling in pharmacy (theoretical notions and drug information), 1993.

**Poster Presentations**

- *Lapointe M*. A 10-year retrospective and descriptive evaluation of the value of a clinical pharmacist in managing intrathecal drug delivery device. International Congress on Clinical Pharmacy, Spring 2004, Paris, France.
- Cheng KT, *Lapointe M*, Ferguson R, Spicer KM. The use of TC-99M DTPA to assess the intrathecal baclofen pump function and shunt patency: A practice innovation illustrated by a patient case. Presented at the American Pharmaceutical Association, San Francisco, CA, 2001. (*Received APhA APPM Presentation Merit Award*)
- Jones C, *Lapointe M*, Patel S, Shah J. Gel based delivery of BCNU. Controlled Release Society, Boston, MA, 1999.
- *Lapointe M*, O'Neil M, Cuddy B. A 5-year retrospective and descriptive evaluation of the value of clinical pharmacists in a neurosurgery spasticity clinic using an intrathetal drug delivery device (Medtronic Synchronomed Pump). Presented at the International Congress on Clinical Pharmacy, Orlando, FL, 1999.
- Haines SJ, *Lapointe M*. "Does ventricular fibrinolysis prevent posthemorrhagic hydrocephalus in preterm infants? - A critical review". Presented at the International Society for Paediatric Neurosurgery, Victoria (Australia), September 1998.
- Reeves ST, Circeo LE, O'Neil MG, *Lapointe M*. Multi-center efficacy trial of long term continuous infusion dosing of rocuronium in critical care patient. Presented at the Sixth International Neuromuscular Blocking Meeting. France, 1997.
- White R, Burgess D, Groke C, Friedrich L, *Lapointe M*. Differences among intensive care units and comparison to hospital susceptibility patterns. Poster presented at the Winter Meeting of American College of Clinical Pharmacists. San Diego, CA, 1994.

**Oral Presentations at Professional Meetings (National and State Associations)**

- “Traumatic Brain Injury”. SC Pediatric Neuroscience Update. Kiawah Island, April 2005.
- “The acute management of hypertension”. Annual meeting – Colorado Academy of Physician Assistants. Denver, February 2005.
- “The future use of erythropoietic agents”. Annual Meeting - American Association of Health-System Pharmacists. Orlando, FL, December 2004.
- “Clinical considerations in the management of hypertensive crisis in hospital settings”. South Carolina Academy of Physician Assistants. Kiawah Island, SC, October 2004.
- “Clinical considerations in the management of hypertensive crisis in hospital settings”. American Association of Critical Care Nurses – Low Country Chapter. Charleston, SC, October 2004.
- “Applied use of alpha-2 adrenergic agonists in neurosurgery – Cost considerations” Congress of Neurological Surgeons. Denver, CO, October 2003.
- “Vasopressin and the management of vasodilatory shock” Mid-American Critical Care Symposium. Toledo, OH, October 2003.
- “Can we really prevent stroke in clinical practice ?” South Carolina Academy of Physician Assistants. Kiawah, SC, October 2003.
- “Advances in the management of PONV” South Carolina Academy of Physician Assistants. Kiawah, SC, October 2003.
- “Low-dose steroids in sepsis – pro and con” Society of Critical Care Medicine (Carolina/Virginia chapter). Raleigh, NC, June 2003.
- “Decision point: Blood management in critical care – Pharmacy perspective” Curriculum planning committee. Carlsbad, CA, May 2003.
- “Clinical pharmacy and ICU outcomes” VHA regional meeting, Memphis, TN, May 2003.
- “Updates in the management of anemia” Florida Society of Health-System Pharmacists (FSHP), Jacksonville, Nov 2002.
- “Intrathecal infusion pumps: advanced dosing techniques.” American Academy of Physical Medicine & Rehabilitation. Orlando, FL, Nov 2002.
- “Anemia”. Georgia Society of Health-System Pharmacists (GSHP). Amelia Island, June 2002.
- “Advances in the treatment of anemia” North Carolina Society of Health-System Pharmacists (NCAP), Charlotte, March 2002.
- “Advances in the treatment of sepsis with organ failure” SC Society of Health-System Pharmacists (SCSHP). Columbia, SC, October 2001.
- “Antiplatelet agents for secondary stroke prevention” South Carolina Academy of Physician Assistants. Hilton Head, SC, October 2002.
- “Anemia after surgery and during critical illness” South Carolina Academy of Physician Assistants. Hilton Head, SC, October 2002.
- “Pharmacology in the management of severe traumatic brain injury” Society of Critical Care Medicine (Carolina/Virginia chapter). Virginia beach, VA, June 2001.
- “Update on Stroke management” SC Society of Hospital Pharmacists, Hilton Head, SC, March 2001.
- “Surgical Prophylaxis” SC Infectious Dis. Pharmacotherapy Symposium. Charleston, 1998.
- “New Drugs” SC Emergency Nurses Association Conference. Charleston, April 1998.
- “CAPSI activities and Pharmacy Practice in Canada” American Pharmaceutical Association, Academy of Students in Pharmacy. Dallas, TX, 1993.

**Oral Presentations at Local and Regional Continuing Education Programs**

- The Management of Hypertensive Crisis in the Hospital Setting, Annual Critical Care Nursing Retreat – MUSC, Charleston, SC, 2005.
- “Updates in the management of hypertensive crisis”  
Pharmacy Education Programs, 2004-5 (Medical Media Communication)  
Programs presented in CA, CO, SC MI, SC.
- “Advances in the management of PONV”  
Pharmacy Education Programs, 2003 (Accel Healthcare Communication)  
Programs presented in MI, NC, SC.
- “Clinical issues with quinolones”  
Navy and Air Force hospitals, Charleston, SC, May 2003.
- “Updates in critical care pharmacotherapy”  
Moses H. Cone Memorial Hospital, Greensboro, NC, April 2003.
- “Erythropoietic agents and Pharmacoeconomics”  
Cleveland Society of Health-System Pharmacists. Akron, OH, Feb 2003.
- “Overview of anemia management”  
Sarasota Regional Society of Health-System Pharmacists. Sarasota, FL, Feb 2003.
- “Anemia management”  
Hospital Pharmacy Education Programs, 2003 (Design Write, Inc.)  
Programs presented in FL, NJ, SC, TN
- “Management of anemia in surgery / critical illness and Updates in critical care”  
Hospital Pharmacy Education Programs, 2002 (Design Write, Inc):  
Programs presented in FL, NC, SC, TN
- “Intrathecal drug delivery”  
MUSC College of Nursing Pain Symposium, Charleston, June 2002.
- “Stroke Prevention and Intervention”  
Annual Drug Update Symposium, Charleston, May 2002.
- “Management of anemia in surgery / critical illness and Updates in critical care”  
Hospital Pharmacy Education Programs, 2001 (Design Write, Inc.)
- “The use of thrombolytic agents in hemorrhagic stroke”  
MUSC Neuroscience Grand Rounds, May 2001
- “Update on Stroke”  
Broadcasted to SC hospitals, Charleston, SC, September 2000.
- “Update in Neurosurgery”  
South Carolina Critical Care Pharmacy Symposium. Charleston, June 2000.
- “Surgical prophylaxis”.  
Pharmacia & Upjohn, Newark, NJ, 1999.
- “The use of an intrathecal baclofen pump to treat spasticity”  
Physical Medicine and Rehabilitation Department Conference. Florence, SC, 1998.

**Oral Scientific Presentations (Institutional)**

- “Neurosciences inservices”  
Neurosciences Intensive care Unit, 2005-
- “Stroke”  
MUSC Med-U-Way, March 2004.
- “Clinical research in neurosurgery”  
MUSC College of Pharmacy Scientific Seminar. September 2002.
- “Pharmacist’s Role in a spasticity clinic: Intrathecal drug delivery system”  
MUSC College of Pharmacy Scientific Seminar. September 2000.
- “Conscious sedation”.  
Nursing Education Program, 2000.
- “Sedation in the ICUs: Clinical practice guidelines”  
MUSC Nursing Education Program, 2000.
- “Pharmacological management of subarachnoid hemorrhage and vasospasms”  
Nursing Continuing Education Program, October 1998.
- “The use of an intrathecal baclofen pump to treat spasticity”  
Physical Medicine and Rehabilitation Department Conference, March 1998.
- “ACLS Drugs”  
MUSC neurology and neurosurgery nurses, 1998.
- “Conscious Sedation”  
MUSC inservice on the new policy and procedure, 1997.
- “Review and Updates on antimicrobial agents”  
MUSC College of Dentistry, 1996.
- “Fosphenytoin: A new antiepileptic”  
MUSC Critical Care Nurses Continuing Education Program, 1996.
- “Management of intracranial hypertension”  
MUSC Critical Care Nurses Continuing Education Program, 1996.
- “The acute management of brain attack: Should we counterattack with thrombolytics”  
Medical University of South Carolina, Residency Seminar, 1996.
- “The use of ondansetron in postoperative nausea and vomiting”  
University of Georgia, Southeastern Residency Conference, 1996.

**National Pharmacy Consultant**

- ESP Pharma: “Nicardipine”, 2004.
- Abbot Laboratories: “Dexmedetomidine”, 2003.
- Xanodyne Pharmacal Inc.: “Xanacal”, 2003.
- Chatham Institute: “Anemia management in the ICU”, 2003-4.
- Armand-Scott, Inc. “Erythropoietic agents”, 2002-2003.
- Ortho-Biotech: “Recombinant erythropoietin alfa”, 2002-3
- Merck: “Ertapenem”, 2001
- Ortho-McNeil: “Levofloxacin”, 2001.
- Pharmacia & Upjohn: “Linezolid”, 1999.

**Research activities**

- Minimal Invasive Surgery plus r-tPA for Intracranial Hemorrhage Evacuation (MISTIE), Co-Principal Investigator, Co-Study Coordinator, 1/1/05-12/31/08, NIH/NINDS/NACABI/Johns Hopkins; \$ 391,539.
- Phase II, Randomized Pharmacokinetic, Dose Finding and Dose Frequency Determination using rt-PA in Intraventricular Hemorrhage, Co-Principal Investigator, Co-Study Coordinator, 9/15/04-9/14/05, FDA/Johns Hopkins; \$ 28,000.
- Phase II, Randomized Pharmacokinetic, Dose Finding and Dose Frequency Determination using rt-PA in Intraventricular Hemorrhage, Co-Principal Investigator, Co-Study Coordinator, 1/1/04-9/14/05, FDA/Johns Hopkins; \$ 35,160.
- International multicenter intraventricular hemorrhage thrombolysis trial, Co-Principal Investigator, Co-Study Coordinator, 1/1/00-12/31/03, FDA/Johns Hopkins; \$ 45,280.
- “International Surveillance Program”.  
Merck Inc.: \$ 3,500; Institutional Co-Principal Investigator at MUSC (2004-2005)
- “International Surveillance Program”.  
Merck Inc.: \$ 3,500; Institutional Co-Principal Investigator at MUSC (2003-2004)
- “Open label, randomized, parallel group study to confirm safety and efficacy of epoetin alfa administered perioperatively vs. the standard care of blood conservation in subject undergoing major elective spinal surgery. Institutional co-investigator and study coordinator, (2003-2004)
- “Intrathecal SNX-111 for refractory pain syndrome”  
Elan Pharmaceutical, \$ 10,000; Institutional Co-Principal investigator, Study Coordinator
- “International Surveillance Program”.  
Merck Inc.: \$ 3,500; Institutional co-investigator (2001-2002).
- “International Surveillance Program”.  
Merck Inc.: \$ 3,500; Institutional co-investigator (2000-2001).
- “International Surveillance Program”.  
Merck Inc.: \$ 2,500; Institutional co-Investigator (1999-2000).
- “A multicenter, randomized, open label study to compare the safety and efficacy of levofloxacin with that of imipenem/cilastatin in the treatment of nosocomial pneumonia”.  
Ortho-McNeil: \$ 20,000; Institutional co-investigator and study coordinator (2000-2001).  
FDA: \$ 12,000; Institutional co-investigator and study coordinator (1999-2000).
- “Development of a gel-based delivery system for BCNU in brain tumor”  
University Research Committee: \$ 12,651; Co-principal investigator (2001).
- Development of a novel drug delivery system for treatment of malignant gliomas.  
American Cancer Society Institutional Research Grant Program: \$ 16,964  
Co-principal investigator (2000).
- “Multicenter safety and efficacy trial of long term infusion dosing of Rocuronium in critical care patients. Organon Inc.: \$ 20,000; Institutional co-investigator and study coordinator
- “Phase I / II open-label, non-randomized, multicenter, dose-escalating study of interstitial 131 I-chTNT-1/B for the treatment of recurrent supratentorial anaplastic astrocytoma and glioma multiforme”. Techniclone; Institutional sub-investigator.
- Trovafloxacin pharmacokinetics in patients with thermal injury” , Co-investigator (1998).
- “Multicenter randomized open label study evaluating the cost effectiveness of amphotericin B colloidal dispersion and amphotericin B in Fungal infections”; Co-investigator (1998).
- “Interaction of Nimodipine with enteral nutrition in critically ill patients”  
Bayer Pharmaceutical Division: \$ 3,000; Principal investigator (1997).
- Comparison of the relationship between susceptibility pattern and drug usage in intensive care units versus the hospital as a whole”. Sub-investigator (1995).

**Educational grants for internal research projects**

- “Drotrecogin Alpha in Sepsis” (2001); Eli Lilly, \$ 3,000
- “Propofol for sedation in neurosurgery” (2000); Astra Zeneca, \$ 1,500
- “Evaluation of sedation in neurosurgery” (1998); Hoffman- La Roche Pharmaceutical, \$ 5,000
- “Guidelines for conscious sedation“ (1998); Hoffman - La Roche Pharmaceutical, \$ 2,000
- “Rocuronium Bromide in critical care patients (1998). Organon Inc, \$ 7,000

**Clinical Projects**

- Medication Use Evaluation:  
“The use of ondansetron for PONV”, 2000; “Surgical prophylaxis in neurosurgery”, 1999;  
“Surgical prophylaxis”, 1998; “Neuromuscular blockers”, 1997; “Stress ulcer prophylaxis”,  
1996; “Development of a pain management protocol in orthopedic patients undergoing total or  
partial hip replacement”, 1996; “The use of ondansetron for postoperative nausea and  
vomiting”, 1996-97.

**Teaching Activities****Pharm.D. Curriculum**

2005-	Meningitis; Calculations (elective) (2 hours)
2003-	Stroke, Epilepsy; Parkinson’s disease, Multiple sclerosis; Alcohol liver disease; Antimicrobial surgical prophylaxis; Phenytoin pharmacokinetics (17 hours)
1996-2002	Antimicrobial surgical prophylaxis; Alcohol liver disease; The acute management and prevention of stroke; Status epilepticus; Phenytoin pharmacokinetics
1998-2001	Pharmacokinetic changes in critically ill patients
1999-2000	Diabetes insipidus and SIADH
1996-1998	Acid-base disorders
1996-2000	Stress ulcer prophylaxis
1998-2000	Nosocomial pneumonia

**B.S. Pharmacy Clinical Therapeutics**

1996-1999	Antimicrobial surgical prophylaxis; Acid-base disorders; Stroke
-----------	---

**Honors and Recognition**

2005	Rho Chi, Honorary member
2005	Kappa Psi, Honorary member
2002	Distinguished Young Pharmacist Award SC Pharmacy Association (South Carolina Pharmacy Association)
2001	Professional Development Award MUSC College of Pharmacy
2001	APhA APPM Presentation Merit Award American Pharmaceutical Association, San Francisco, CA, 2001.
2000	Preceptor of the Year South Carolina Chapter – American Society of Health-System Pharmacists
2000	Applause Award Medical University of South Carolina.
2000	Nomination for Preceptor of the Year Pharm.D. Class of 2000
1999	Nomination for Preceptor of the Year Residency class of 1999
1999	Nomination for Preceptor of the Year Pharm.D. Class of 1999
1996	Division of information - Development Awards United States Pharmacopeia
1992-94	Scholarship - Advanced Training in Clinical Practice Canadian Foundation for Pharmacy
1993	<i>J. Antonin Marquis</i> Award Quebec Pharmacy Association
1992-93	Past-President Award Canadian Pharmaceutical Association
1992-93	Nomination for Student of the year Pharmacy Class of 1993
1991	Local representative Local at National Compounding Competition Laval University, School of pharmacy, Quebec (Canada)
1991-92	Nomination for the <i>Centennial Scholar</i> Award Laval University, School of pharmacy, Quebec (Canada)
1990-91	Eli Lilly Award Laval University, School of pharmacy, Quebec (Canada)